Naringin significantly inhibited endothelial-to-mesenchymal transition and alleviated PAH progression induced by treatment with TGFβ1, enhanced endothelial marker expression, and inhibited the activation of the ERK and NF-κB signaling pathways. Here, TGFB1 is linked to pulmonary arterial hypertension.